G1 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Caleb Smith, Malcolm Kuna and Priyanka Grover from the team. Our next presenting company is G1 Therapeutics. And presenting on behalf of the company, we have CEO, Jack Bailey.
I want to remind all the attendees of this session that there is a Ask a Question feature in the portal. And if you would like me to ask a question on your behalf, put it in the portal, and I'm happy to do that.
With that, Jack, take it away.
Great. Thank you, Anupam.
I'm excited to be presenting today because G1 did have a very, very busy 2021, and we have an even more exciting 2022 in front of us. I'll share with you why we are confident. We'll continue to grow COSELA in our initial indication of extensive stage small cell lung cancer and how small cell
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |